Related references
Note: Only part of the references are listed.Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
M. R. Bishop et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models
Kevin P. Nishimoto et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2022)
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
Mehdi Hamadani et al.
BLOOD ADVANCES (2022)
Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity
Hind Rafei et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant
Susan Prockop et al.
BLOOD (2021)
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients ( Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study
Manali Kamdar et al.
BLOOD (2021)
Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer
May Daher et al.
CANCER DISCOVERY (2021)
Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
Elise A. Chong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming
Federico Simonetta et al.
CLINICAL CANCER RESEARCH (2021)
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Jay Y. Spiegel et al.
NATURE MEDICINE (2021)
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy
Jay Y. Spiegel et al.
BLOOD (2021)
Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma
Forat Lutfi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Durable Remission Following “Off-the-Shelf” Chimeric Antigen Receptor (CAR) T-Cells in Patients with Relapse/Refractory (R/R) B-Cell Malignancies
Kevin J. Curran et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
'Off-the-shelf' allogeneic CAR T cells: development and challenges
S. Depil et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tuning the Antigen Density Requirement for CAR T-cell Activity
Robbie G. Majzner et al.
CANCER DISCOVERY (2020)
Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
Meir Rozenbaum et al.
FRONTIERS IN IMMUNOLOGY (2020)
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma
Erin A. Dean et al.
BLOOD ADVANCES (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Point mutation inCD19facilitates immune escape of B cell lymphoma from CAR-T cell therapy
Zhen Zhang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Lingering effects of chemotherapy on mature T cells impair proliferation
Rajat K. Das et al.
BLOOD ADVANCES (2020)
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
Frederick L. Locke et al.
BLOOD ADVANCES (2020)
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Laetitia Vercellino et al.
BLOOD ADVANCES (2020)
Mechanisms of resistance to CAR T cell therapy
Nirali N. Shah et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
Sneha Ramakrishna et al.
CLINICAL CANCER RESEARCH (2019)
Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges
Alexandros Nianias et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV plus PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program
Susan Prockop et al.
BLOOD (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Naive T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers
Rajat K. Das et al.
CANCER DISCOVERY (2019)
Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia
Franziska Blaeschke et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
Haneen Shalabi et al.
HAEMATOLOGICA (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
Haneen Shalabi et al.
HAEMATOLOGICA (2018)
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation
Lauren P. McLaughlin et al.
BLOOD (2018)
T cell dysfunction in pediatric cancer patients at diagnosis and after chemotherapy can limit chimeric antigen receptor potential
Rajat K. Das et al.
CANCER RESEARCH (2018)
Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting
Antonia Rotolo et al.
CANCER CELL (2018)
Molecular Mechanisms Directing Migration and Retention of Natural Killer Cells in Human Tissues
Roberta Castriconi et al.
FRONTIERS IN IMMUNOLOGY (2018)
Aged CAR T Cells Exhibit Enhanced Cytotoxicity and Effector Function but Shorter Persistence and Less Memory-like Phenotypes
Hiroshi Kotani et al.
BLOOD (2018)
Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy
Rebecca Gardner et al.
BLOOD (2018)
Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma
Hui Yu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Integration of a CD19 CAR into the. TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
Daniel T. MacLeod et al.
MOLECULAR THERAPY (2017)
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem et al.
NATURE (2017)
T memory stem cells in health and disease
Luca Gattinoni et al.
NATURE MEDICINE (2017)
Donor CD19 CART cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
Arnab Ghosh et al.
NATURE MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Waseem Qasim et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation
Melissa Mavers et al.
Frontiers in Immunology (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
D. Sommermeyer et al.
LEUKEMIA (2016)
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
Xiuli Wang et al.
BLOOD (2016)
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
Marianna Sabatino et al.
BLOOD (2016)
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Partow Kebriaei et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
Cameron J. Turtle et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies
Nathan Singh et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation
Sarah Morin-Zorman et al.
FRONTIERS IN IMMUNOLOGY (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy
Andras Heczey et al.
BLOOD (2014)
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
Catherine M. Bollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Clinical applications of gamma delta T cells with multivalent immunity
Drew C. Deniger et al.
FRONTIERS IN IMMUNOLOGY (2014)
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
James N. Kochenderfer et al.
BLOOD (2013)
Simplified process for the production of anti-CD19-CAR-engineered T cells
Barbara Tumaini et al.
CYTOTHERAPY (2013)
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy
Maria Themeli et al.
NATURE BIOTECHNOLOGY (2013)
The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion
Viola Biberacher et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
γδ T cell effector functions: a blend of innate programming and acquired plasticity
Marc Bonneville et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Harlan S. Robins et al.
BLOOD (2009)
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Hiroyuki Fujisaki et al.
CANCER RESEARCH (2009)
Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells:: potential for adoptive immunotherapy and allodepletion
AE Foster et al.
BLOOD (2004)
Share Paper
